Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high... see more

TSX:SZLS - Post Discussion

View:
Post by NoGambleNoFutur on Jan 25, 2021 12:11am

Revenues

Hey guys, I've done some research about this company, but I have a question regarding its revenues, if someone can help me out.

Revenues 2020

Q1 2020: 11.3k
Q2 2020: 99.8k
Q3 2020: 1.4M (increase due to covid-19)

Note 1 of the financial statements says this:

"The Company’s lead product, ColonSentry®, is a blood test to determine an individual’s current risk for having colorectal cancer."

My question is the following: What is generating the revenues of 11.3k and 99.8k in Q1 and Q2? Is it the sale of their product, ColonSentry? I'm just trying to understand where these revenues are coming from. Thanks.

Comment by Oilminerdeluxe on Jan 25, 2021 5:38am
Covid tests are the only real income of worth. ColonSentry can however be used in other ways. Like being shoved up the bashers' a... If revenue is the same this Q, or slightly higher, I will be happy. I supect costs will have increased a lot as they prepare for the launch of Aristotle, staff hirings etc etc.  I have developed a fear whenever JHT speaks of sales and revenue, so I do not ...more  
Comment by NoGambleNoFutur on Jan 25, 2021 9:49am
Ok, but if revenues are mostly generated due to covid-19, they even said it's temporary. It's a bit worrisome if their previous revenues of 100k were generated by their product Colonsentry. Even after developing Aristotle, why would I expect them to generate millions in sales? I understand it detects up 10 cancers from a blood test, but if they don't have a good sales plan, it could be ...more  
Comment by Spideysenses20 on Jan 25, 2021 9:53am
covid is gonna be around for years now they already predicted we will be dealing with covid19 til 2025 so you can expect revenue from covid for another 5 years minimum
Comment by frewil11 on Jan 25, 2021 10:03am
I watched the video and it looks like Stage Zero is going to count on the mobile phlebotomists a great deal because Tripp did mention that there is a lot of problems with trying to go the route with health care insurance companies like Blue Cross for example he said , I was hoping that it was going to be part of your health care plan and paid for through it .
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities